Daniel Wolff News Today

[applause] daniel wolff is an awardwinning author, poet and agree any nominee from the hudson river his new book which will officially be published on tuesday is grownup anger the connected mysteries of bob dylan, Woody Guthrie, and the calumet massacre of 1913. As the title suggests, it gives three tales the biographies of bob dylan, Woody Guthrie and the back story of the tragedy in michigan, the tragedy he puts in the context of the Early Labor Movement in this country. The review calls this ...

Community, i didnt have any family here. I didnt have any friends here. But i had heard about samuel which i had never heard about before in 2009 when i was looking for a setting for one of the stories i did not recession effect for the washington post. And somebody mentioned to me there was a community in wisconsin just had lost a big old General Motors plant. And i thought that was interesting but i didnt come here at the time because this is just happened. And eyes you know a lot of people we...

I want to give a special thank you to the sponsors. Todays Program Broadcast on cspan2 book tv. If we have time at the end of the q a session with the author, we ask that you use the microphone provided. Before we begin todays program we ask that you silenced her phones and turn off the flash and now. [applause] anan awardwinning author, kuwat and grammy nominee from new york city on the hudson river. His new book that willhi officially be published on tuesday, so we are in the future right now ...

This article will appear in the January 2024 issue of Evidence-Based Oncology.™ Each year, our January issue features a recap of proceedings from the American Society of Hematology Meeting and Exposition.

Axatilimab can produce durable responses in patients with recurrent or refractory chronic GVHD, a phase 2 trial suggests.

Highest overall response rate and least toxicity seen with lowest dose

Axatilimab induced rapid and durable responses with an acceptable toxicity profile at all doses analyzed with highest efficacy observed at the 0.3-mg/kg dose in patients with recurrent or refractory chronic graft-vs-host disease.

WILMINGTON, Del. & WALTHAM, Mass.--(BUSINESS WIRE)--Dec 10, 2023--

- Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg dose achieving a complete or partial response within the first six months of treatment - Data are...

It was 10 o’clock on an August morning, and the sun was already broiling.